Receives from NIH A Grant of Exclusive Patent License of Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
July
Acquires China promotion rights of Atom-Hitech (HTA) cardiac imaging agent Technetium (99mTc) Mibi.
June
Establishes Sinotau Cloud Pharmaceutical Technology Co.,Ltd. to initiate the promotion of radiopharmaceuticals.
2017
December
Establishes Jiangsu Sinotau Molecular Imaging
September
Establishes Guangdong Sinotau Molecular Imaging
August
Sinotau signs license agreement with Piramal Imaging S.A., for development and commercialization of Neuraceq, a novel Aβ amyloid imaging diagnostic agent for Alzheimer’s disease, in China.
July
SinotauJuly, Sinotau obtains the exclusive patent license for the manufacture of positron-based myocardial perfusion imaging agent [18F] heart ketone injection (MyoZone [18F] Injection).
July
Sinotau signs exclusive agreement with Cerveau for development and commercialization of MK-6240, the world leading tau protein diagnostic drug for Alzheimer’s disease, in China
June
Sinotau completes B round financing for 150 million RMB. Qiming Venture Capial is the lead investor. Several Sinotau key employees became shareholders of the company.
2016
December
Cerveau signs exclusive license agreement with Merck Sharp & Dohme for the global development and commercialization of early stage investigational imaging agent MK-6240.
November
Sinotau obtains 130 million RMB in A round financing
June
Sinotau signs exclusive agreement with FluoroPharma Medical Imaging, Inc., an US company, to develop and commercialize cardiac imaging products CardioPET and BFPET in China and Canada.
March
Sinotau acquires a biological antibody development platform, including CTB006, in the early stages of clinical trials.
February
Sinotau and Enigma Biomedical Group establishes a US joint venture to form Cerveau Technologies, Inc., in Boston.
2015
November
Sinotau acquires significant shares of Enigma Biomedical Group, a Canadian company.
October
Sinotau USA, Inc, a wholly owned subsidiary of Sinotau, is established in Boston.
2014
August
Sinotau signs an agreement with Navidea Biopharmaceuticals Inc., for the exclusive China distribution rights of Technetium (99mTc) tilmanocept, the first and only receptor-targeted lymphatic mapping agent approved by the FDA.
2009
March
Sinotau launches several relevant generic products in the Chinese market and becomes a fully vertically integrated company; expanding business operations into R&D, manufacturing, marketing and sales.
2008
February
Sinotau establishes first cooperation frameworks with overseas multinational pharma players to jointly develop the Chinese market.
2005
January
Sinotau is founded. Initially it is envisioned as a drug development company.
